Comparison 1.

Mepolizumab (SC) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Rate of exacerbations requiring systemic corticosteroids	2	936	Rate Ratio (Random, 95% CI)	0.45 [0.36, 0.55]
1.1 Eosinophilic	2	936	Rate Ratio (Random, 95% CI)	0.45 [0.36, 0.55]
2 Rate of exacerbations requiring emergency department treatment or admission	2	936	Rate Ratio (Random, 95% CI)	0.36 [0.20, 0.66]
2.1 Eosinophilic	2	936	Rate Ratio (Random, 95% CI)	0.36 [0.20, 0.66]
3 Rate of exacerbations requiring admission	2	936	Rate Ratio (Random, 95% CI)	0.31 [0.13, 0.73]
3.1 Eosinophilic	2	936	Rate Ratio (Random, 95% CI)	0.31 [0.13, 0.73]
4 Health‐related quality of life (ACQ)	2	936	Mean Difference (Random, 95% CI)	‐0.42 [‐0.56, ‐0.28]
4.1 Eosinophilic	2	936	Mean Difference (Random, 95% CI)	‐0.42 [‐0.56, ‐0.28]
5 Health‐related quality of life (SGRQ)	2	936	Mean Difference (Random, 95% CI)	‐7.40 [‐9.50, ‐5.29]
5.1 Eosinophilic	2	936	Mean Difference (Random, 95% CI)	‐7.40 [‐9.50, ‐5.29]
6 Pre‐bronchodilator FEV1 (litres)	2	936	Mean Difference (Random, 95% CI)	0.11 [0.06, 0.17]
6.1 Eosinophilic	2	936	Mean Difference (Random, 95% CI)	0.11 [0.06, 0.17]
7 Serious adverse events	2	936	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.41, 0.97]
7.1 Eosinophilic	2	936	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.41, 0.97]
8 Adverse events leading to discontinuation	2	936	Risk Ratio (M‐H, Random, 95% CI)	0.45 [0.11, 1.80]
8.1 Eosinophilic	2	936	Risk Ratio (M‐H, Random, 95% CI)	0.45 [0.11, 1.80]